InterMune Inc (NASDAQ:ITMN)

Data as of Sep 19
 +0.15 / +0.20%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

InterMune, Inc. is a biotechnology company that is focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. It is focused on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The company's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. InterMune was founded in 1998 and is headquartered in Brisbane, CA.

Contact Information

InterMune, Inc.
3280 Bayshore Boulevard
Brisbane California 94005-1021
P:(415) 466-2200
Investor Relations:
(415) 466-2228



Individual stakeholders7.67%
Mutual fund holders57.15%
Other institutional31.18%

Top Executives

Daniel G. WelchChairman, President & Chief Executive Officer
John C. HodgmanExecutive VP, Chief Financial & Accounting Officer
Marianne T. ArmstrongSVP, Chief Medical Affairs & Regulatory Officer
Scott D. SeiwertSenior VP-Research & Technical Development
Jonathan A. LeffExecutive Vice President-Research & Development

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.